Successfully Exports Psilocybin from its Jamaica Facility The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products
VANCOUVER, BC, Nov. 22, 2021 /CNW/ - Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is pleased to announce it has successfully exported naturally derived psilocybin from its facility in Jamaica.
The importation of the naturally derived psilocybin into Canada was completed after the Company entered into a supply agreement with Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Based out of Victoria, British Columbia, Nectar Health Sciences Laboratory Division Inc. has a Controlled Substance Dealer's License for the relevant psychedelic compounds issued by Health Canada. Under that license, Nectar was granted an import permit, pursuant to the provisions of the Controlled Drugs and Substances Act and the Food and Drugs Regulations.
https://www.newswire.ca/en/releases/archive/November2021/22/c2170.html